Australia's Benitec Biopharma plans to list on the Nasdaq in an initial public offering in the United States that would raise as much as $70 million, according to a June 23 proxy notice to existing shareholders.
The company, listed on the Australian Stock Exchange, informed the U.S. Securities and Exchange Commission of its intention to proceed with an IPO, saying it would use the funds for its working capital and general corporate purposes.
Benitec is developing gene therapies for hepatitis C based on RNA interference.
- here's the Benitec proxy form